

Validation of the Idylla GeneFusion Assay to detect fusions and MET exon-skipping in non-small cell lung cancers

Gilson, et al. Sci Rep 13, 12909 (2023). doi:10.1038/s41598-023-39749-4

STUDY AIM

Gene fusions and MET exon skipping drive oncogenesis in 8–9% and 3% of non-small cell lung cancers (NSCLC) respectively. Their detection are essential for the management of patients since they confer sensitivity to specific targeted therapies with significant clinical benefit over conventional chemotherapy. The aim of the study is to evaluate the Idylla™ GeneFusion Assay, a fully-automated test that can identify a panel of specific gene fusions (including 16 specific ALK fusions, 13 ROS1 fusions, 7 RET fusions and MET exon 14 skipping) as well as expression imbalance (in ALK, ROS1, RET, NTRK1, NTRK2 and NTRK3 genes) without pre-analytical RNA extraction.

STUDY DESIGN

In this retrospective study, an evaluation of the Idylla™ GeneFusion Assay was performed in **35 clinical FFPE** specimens from NSCLC patients using IHC/FISH and RNASeq as the gold standards. This included the analysis of 11 clinical samples that did not reach RNA quality requirements for RNASeq.

RESULTS

PERFORMANCE

Idylla™ versus NGS (RNAseq)

100% sensitivity (18/18)

100% specificity (5/5)

Idylla™ versus IHC/FISH

91.7% sensitivity (11/12)

89.5% specificity (17/19)

Idylla™ validity


94.3% (33/35)

SALVAGE OF INCONCLUSIVE NGS SAMPLES


Idylla™ GeneFusion Assay was able to retrieve **90.9%** (10/11) of the FFPE samples that were found inconclusive by RNASeq due to insufficient RNA quality. Those included two samples **with actionable alterations** detected by Idylla™ that could benefit from targeted therapies.

PROPOSED LABORATORY WORKFLOWS

A) The Idylla GeneFusion assay could represent a backup alternative for samples with insufficient RNA quality for broader molecular analyses



B) One-day workflow integrating the Idylla GeneFusion assay for the rapid detection of hotspots alterations in NSCLC



C) Comprehensive workflow integrating the Idylla GeneFusion assay as a first step for urgent clinical cases or as a prescreening tool




Figure 1. Proposition of laboratory workflows integrating the Idylla GeneFusion assay.

The Idylla™ GeneFusion Assay appears as a fast and reliable alternative to reference methods to detect gene fusions.

Due to its minimal hands-on-time and low turnaround time, it could be easily integrated into laboratory workflows in order to give more rapid tumor molecular profiles or retrieve samples rejected by other molecular techniques.

Biocartis NV
Generaal De Wittelaan 11B
2800 Mechelen, Belgium
+32 15 632 888
www.biocartis.com
customerservice@biocartis.com

Biocartis US, Inc
2 Pierce Place, Suite 1510
Itasca, IL 60143
1-844-443-9552
www.biocartis.com/US
customerserviceUS@biocartis.com



Gilson, P., Pouget, C., Belmonte, R. et al. Validation of the Idylla GeneFusion assay to detect fusions and MET exon-skipping in non-small cell lung cancers. *Sci Rep* 13, 12909 (2023). <https://doi.org/10.1038/s41598-023-39749-4> (Lorraine Cancer Institute (ICL), Vandoeuvre-les-Nancy, France)

Idylla™ Platform is CE-marked in Europe in compliance with EU IVD Regulation 2017/746, cleared for sale in the US and registered in many others countries. Idylla™ GeneFusion Assay is for Research Use Only (RUO), not for use in diagnostic procedures. This product contains SuperScript™ III Reverse Transcriptase and is provided subject to a license under patents or patent applications owned by or licensed to Life Technologies Corporation, which license is limited to the human diagnostic field and research field and specifically excludes applications in forensics (including human identity testing). The SuperScript™ III trademark is owned by Life Technologies Corporation. Patents US 7,700,339, 8,168,383, 8,481,279, 8,486,645, 8,232,060, 8,288,102, 8,377,642, 9,988,688, 9,523,130, 9,096,855, 10,526,661, 9,364,477, 9,539,254, 10,551,383 and pending US applications and all their respective foreign equivalents under license from Cell Signaling Technology, Inc.

The data and conclusions provided in this external publication were derived externally by third parties and have not been validated in the development of the Idylla™ GeneFusion Assay or included in the product's current labeling by Biocartis NV. Biocartis NV products are designed to be used as described in the product-specific Instructions For Use (IFU).

Idylla™ is available for sale in Europe, the US and many other countries. Please check availability with a Biocartis representative. Biocartis and Idylla™ are registered trademarks in Europe, the US and many other countries. The Biocartis and Idylla™ trademarks and logos are used trademarks owned by Biocartis. © January 2024, Biocartis NV. All rights reserved